<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046795</url>
  </required_header>
  <id_info>
    <org_study_id>REV-3001</org_study_id>
    <nct_id>NCT05046795</nct_id>
  </id_info>
  <brief_title>Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase III clinical study to assess the efficacy and safety of Revefenacin&#xD;
      inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to&#xD;
      placebo in a population of Chinese subjects with moderate to very severe COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, double blind, placebo-controlled, parallel group&#xD;
      study, randomizing approximately 320 male or female moderate-very severe COPD subjects.&#xD;
      Subjects will receive study drug for 12 weeks. Treatments to be received during the study&#xD;
      will include one of the following, administered using a centrally-provided, standard jet&#xD;
      nebulizer and compressor via a mouthpiece: A. Revefenacin inhalation solution 175 mcg Quaque&#xD;
      die (QD). B. Placebo inhalation solution QD. Subjects will have approximately 6 clinic visits&#xD;
      (encompassing a screening period of up to 30 days and a treatment period of 12 weeks), and a&#xD;
      follow-up telephone call 1-2 weeks after the End of Treatment (EoT) visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double-blind, placebo-control, parallel group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 on Day 85</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Change from Baseline (Day 1, pre-dose) trough FEV1 on Day 85</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Revefenacin inhalation solution 175 mcg QD.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revefenacin inhalation solution 175 mcg QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo inhalation solution QD.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhalation solution QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revefenacin 175 mcg in 3 ML Inhalation Solution</intervention_name>
    <description>Revefenacin</description>
    <arm_group_label>Revefenacin inhalation solution 175 mcg QD.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo inhalation solution QD</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo inhalation solution QD.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Key inclusion criteria include:&#xD;
&#xD;
               -  Males and females of Chinese ethnicity, at least 40 years of age. Females may be&#xD;
                  of either childbearing or non-childbearing potential. All females of childbearing&#xD;
                  potential must be using an acceptable, highly effective method of contraception&#xD;
                  and have a negative pregnancy test at screening.&#xD;
&#xD;
               -  A clinical diagnosis for at least 6 months prior to screening of COPD according&#xD;
                  to Global Initiative for Chronic Obstructive Lung Disease(GOLD) guidelines.&#xD;
&#xD;
               -  Subject is capable of performing reproducible spirometry maneuvers as described&#xD;
                  by current American Thoracic Society/European Respiratory Society (ATS/ERS)&#xD;
                  Guidelines and has a post-ipratropium (500 mcg nebulized) Forced Expiratory&#xD;
                  Volume in&#xD;
&#xD;
                  1 second(FEV1)/Forced Vital Capacity(FVC) ratio &lt;0.7 at Visit 2.&#xD;
&#xD;
               -  Subject has moderate to very severe COPD with a post-ipratropium (500 mcg&#xD;
                  nebulized) FEV1 less than 80% of predicted normal (using the Global Lung Function&#xD;
                  Initiative reference range; ) and an absolute FEV1 &gt;700 mL at Visit 2&#xD;
&#xD;
               -  Current smoker or ex-smoker, with a history of at least 10 pack-years of tobacco&#xD;
                  smoking. Ex-smokers must have stopped smoking &gt;6 months prior to Visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Key exclusion criteria include:&#xD;
&#xD;
               -  Previously dosed with Revefenacin.&#xD;
&#xD;
               -  Current diagnosis of asthma.&#xD;
&#xD;
               -  Alpha-1 anti-trypsin deficiency.&#xD;
&#xD;
               -  Other chronic or active respiratory disorder (e.g., clinically significant [as&#xD;
                  determined by the Investigator] bronchiectasis, pulmonary fibrosis, sarcoidosis,&#xD;
                  pneumoconiosis, active tuberculosis).&#xD;
&#xD;
               -  Symptoms of, or treatment for an Acute Exacerbation of COPD(AECOPD) requiring&#xD;
                  antibiotics and/or oral/systemic corticosteroids or in-patient hospitalization&#xD;
                  during the 28 days preceding screening or during the screening period between&#xD;
                  Visit 1 and Visit 3.&#xD;
&#xD;
               -  Pneumonia requiring hospitalization within 28 days prior to screening or during&#xD;
                  the screening period between Visit 1 and Visit 3.&#xD;
&#xD;
               -  Lower respiratory tract infection requiring treatment with antibiotics during the&#xD;
                  28 days preceding screening or during the screening period between Visit 1 and&#xD;
                  Visit 3.&#xD;
&#xD;
               -  History or presence of pulmonary hypertension, respiratory failure, cor pulmonale&#xD;
                  or right ventricular failure which may impact the safety of the subject in the&#xD;
                  clinical judgement of the Investigator.&#xD;
&#xD;
               -  History of pulmonary lobectomy, lung volume reduction surgery, or lung&#xD;
                  transplantation.&#xD;
&#xD;
               -  Use of supplemental oxygen therapy for more than 15 hours per day (includes&#xD;
                  night-time use).&#xD;
&#xD;
               -  Subjects with hepatic impairment.&#xD;
&#xD;
               -  Subject suffers from any medical condition that would preclude the use of inhaled&#xD;
                  anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic&#xD;
                  hyperplasia, bladder neck obstruction, or urinary retention.&#xD;
&#xD;
               -  Subjects who are unable to stop any of the following medications, and refrain&#xD;
                  from their use throughout the study until the final dose of study drug:&#xD;
&#xD;
                    -  Short-acting β2 agonists (except study-supplied salbutamol).&#xD;
&#xD;
                    -  Short-acting anticholinergic agents (except those used for reversibility&#xD;
                       testing).&#xD;
&#xD;
                    -  Long-acting anticholinergics (except study supplied medication).&#xD;
&#xD;
                    -  Combination β2 agonists/anticholinergic agents.&#xD;
&#xD;
                    -  Combination β2 agonists/inhaled corticosteroids/anticholinergic agents.&#xD;
&#xD;
                    -  Phosphodiesterase 4 inhibitors.&#xD;
&#xD;
                    -  Theophyllines.&#xD;
&#xD;
                    -  Leukotriene inhibitors.&#xD;
&#xD;
                    -  Orally inhaled nedocromil or cromolyn sodium.&#xD;
&#xD;
                    -  Oral or parenteral corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dik WH Ng, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dik WH Ng, PhD</last_name>
    <phone>+44 (0)1304 626895</phone>
    <email>dik.ng@viatris.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Revefenacin</keyword>
  <keyword>Long-acting muscarinic receptor antagonist(LAMA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

